Gefitinib-linked triazole derivative as well as preparation method and application thereof

By combining gefitinib with 1,2,3-triazolyl groups, design and synthesize gefitinib-linked triazolazol derivatives, the inadequate inhibitory activity of gefitinib on wild-type lung cancer cells was solved. The problem has achieved effective inhibition of lung cancer cells and targeted therapeutic effects on migration and metastasis.

CN118978513AActive Publication Date: 2024-11-19HENAN JIAHEKANG BIOLOGICAL FOOD TECH CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411047230.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-01-17
Filing Date
2024-08-01
Publication Date
2024-11-19
Estimated Expiration
2044-08-01

AI Technical Summary

Technical Problem

The existing gefitinib has weak inhibitory activity on wild-type lung cancer cells, making it difficult to effectively inhibit the migration and metastasis of lung cancer cells.

Method used

By combining gefitinib with 1,2,3-triazolyl groups, a series of gefitinib-linked triazolyl derivatives were designed and synthesized, and the compound was prepared by click reaction and other methods, and the compound was prepared by multiple methods. Step reactions result in a structurally novel derivative used to target MMP9 to inhibit the migration and metastasis of lung cancer cells.

Benefits of technology

This compound has a significant inhibitory effect on wild-type lung cancer cells, can effectively inhibit the migration and metastasis of lung cancer cells, and induce DNA damage, showing an anti-tumor activity better than gefitinib itself.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978513A_ABST
    Figure CN118978513A_ABST
Patent Text Reader

Abstract

The invention discloses a gefitinib-linked triazole derivative as well as a preparation method and application thereof, and belongs to the technical field of medicine synthesis. The key point of the technical scheme of the invention is as follows: the gefitinib-linked triazole derivative molecule has a structure # imgabs0 #, wherein R is a benzyl structure. The invention designs and synthesizes a gefitinib linked triazole derivative with a novel structure, and the compound has a good inhibition effect on wild type lung cancer tumor cells, and can target MMP9 as an MMP9 inhibitor so as to inhibit migration and metastasis of wild type lung cancer tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug synthesis, and specifically relates to a gefitinib-linked triazole derivative and a preparation method and application thereof. Background Art

[0002] Gefitinib is a first-generation targeted therapy drug that can bind to the epidermal growth factor receptor, thereby inhibiting the proliferation of tumor cells and the growth of new blood vessels. Gefitinib (trade name: Iressa), the first epidermal growth factor receptor tyrosine kinase inhibitor developed by AstraZeneca, has a chemical name: 4-(3-chloro-4-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline. It was first launched in Japan in July 2002 and is mainly used for the treatment of non-small cell lung cancer. Its mechanism of action is mainly to inhibit the tyrosine kinase epidermal growth factor receptor (EGFR). It targets EGFR and competitively binds to EGFR at the highly conserved adenosine triphosphate (ATP) binding site of EGFR, inhibiting EGF receptors, promoting cell apoptosis, and inhibiting tumor angiogenesis. It has a very broad prospect for clinical application. However, with the marketing of gefitinib, it has a good inhibitory effect on EGFR mutant lung cancer cells, but its inhibitory activity against wild-type lung cancer cells is weaker than that against mutant lung cancer cells. We want to improve the inhibitory activity against wild-type lung cancer cells by modifying the EGFR-TKI structure.

[0003] The 1,2,3-triazole structure is a very important class of nitrogen-containing heterocyclic compounds. It is a five-membered heterocyclic ring constructed by 3 nitrogen atoms and 2 carbon atoms, and its molecular formula is C2N3H3. 1,2,3-triazole has a special planar rigid structure, which gives it a strong ability to embed into DNA. It also has a large dipole moment and can form various non-covalent interactions with different biological targets, such as hydrophobic, hydrogen bonds, van der Waals forces, and dipole-dipole bonds. In addition, the structural characteristics of 1,2,3-triazole allow it to be an electronic equivalent substitute for amides, esters, carboxylic acids, olefin rigid analogs, etc., so it has a broad spectrum of biological activity and is often used as an important molecular building block for the synthesis of active compounds, such as the preparation of antibacterial, antimalarial, antifungal, antiviral, antituberculosis and anticancer active compounds, etc., and has a wide range of applications in the field of medicinal chemistry. There are many clinical drugs that have enhanced their original biological activities or acquired new biological activities after being modified with 1,2,3-triazole. For example, the anti-HIV drug zidovudine uses the structural characteristics of an azide group to react with terminal acetylene compounds through click chemistry to obtain compounds with 1,2,3-triazole, which have inhibitory effects on Escherichia coli and Staphylococcus aureus.

[0004] In order to find compounds with good inhibitory effects on EGFR wild-type lung cancer cells, we modified gefitinib through click reaction and introduced 1,2,3-triazole groups into its structure, hoping that it would have an inhibitory effect on wild-type lung cancer cells. We used gefitinib as a positive control and used CCK-8 method to test the in vitro antitumor activity of EGFR wild-type lung cancer cells H1299, A549 and H1437, and studied the effects on tumor cell clone formation, migration ability and apoptosis. Summary of the invention

[0005] The technical problem solved by the present invention is to provide a gefitinib-linked triazole derivative which is simple and easy to operate, has cheap and readily available raw materials, has high reaction efficiency and has a good inhibitory effect on tumor cells, and a preparation method thereof.

[0006] The present invention adopts the following technical solution to solve the above technical problems. Gefitinib is linked to a triazole derivative, which is characterized by having the following structure: Wherein R is a benzyl structure.

[0007] The method for preparing gefitinib-linked triazole derivatives of the present invention is characterized by:

[0008] The method for preparing gefitinib-linked triazole derivatives of the present invention is characterized in that the specific steps in the preparation process are:

[0009] (1): A certain amount of methyl 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate is dissolved in an acetic acid solution, the system is cooled to below 10°C, a certain amount of a mixed solution of nitric acid and sulfuric acid is added dropwise, the system is gradually heated to room temperature after the addition is completed, the system reacts at a certain temperature for several hours, and the reaction is monitored by TLC. After the reaction is completed, water is added to the system to quench the reaction, ethyl acetate is extracted, the water is dried over anhydrous sodium sulfate, and the crude product is evaporated to dryness and purified by column chromatography to obtain methyl 2-nitro 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate; the molar ratio of the feed amount of methyl 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate to nitric acid and sulfuric acid is 1:1-1.3:1-1.3; the reaction temperature is 20-50°C.

[0010] (2): A certain amount of methyl 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate is dissolved in a nitromethane solution, the system is cooled to below 10°C, a certain amount of methyl nitrate is added dropwise, the system is gradually heated to room temperature after the addition is completed, the system reacts at a certain temperature for several hours, and the reaction is monitored by TLC. After the reaction is completed, water is added to the system to quench the reaction, ethyl acetate is extracted, the water is dried over anhydrous sodium sulfate, and the crude product is evaporated to dryness and purified by column chromatography to obtain methyl 2-nitro 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate; the molar ratio of the feed amount of methyl 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate to methyl nitrate is 1:1-1.3; the reaction temperature is 0-40°C.

[0011] (3): A certain amount of 2-nitro 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester is dissolved in anhydrous methanol solution, and a certain amount of palladium carbon is added in batches at room temperature. After the addition is completed, the system is reacted at the corresponding temperature for several hours, and the reaction is monitored by TLC. After the reaction is completed, the system filters out excess palladium carbon, evaporates to dryness, and the crude product is purified by column chromatography to obtain 2-amino 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester; the molar ratio of the feed amount of 2-nitro 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester to palladium carbon is 1:0.02~0.2; the reaction temperature is 20~60°C.

[0012] (4): A certain amount of methyl 2-amino-4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate and ammonium formate are dissolved in a DMF solution, the system is heated to react for several hours, and the reaction is monitored by TLC. After the reaction is completed, water is added to the system to quench the reaction, and the mixture is extracted with ethyl acetate, dried over anhydrous sodium sulfate, evaporated to dryness, and the crude product is purified by column chromatography to obtain 7-methoxy-6-(3-morpholinopropoxy)quinazolin-4(3H)-one; the molar ratio of the methyl 2-amino-4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate to ammonium formate is 1:3 to 1.6; and the reaction temperature is 120 to 170°C.

[0013] (5): A certain amount of 2-amino 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester and ammonium formate are dissolved in DMA or DMSO solution, the system is heated to react for several hours, and the reaction is monitored by TLC. After the reaction is completed, water is added to the system to quench the reaction, and the mixture is extracted with ethyl acetate, dried over anhydrous sodium sulfate, evaporated to dryness, and the crude product is purified by column chromatography to obtain 7-methoxy-6-(3-morpholinopropoxy)quinazolin-4(3H)-one; the molar ratio of the 2-amino 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester to ammonium formate is 1:3-1.6; the reaction temperature is 60-100°C, the microwave reaction gear is set to 6-8 gears, and the time is set to: 15min-30min.

[0014] (6): A certain amount of 7-methoxy-6-(3-morpholinopropoxy)quinazolin-4(3H)-one was dissolved in a phosphorus oxychloride solution, and the system was heated to react for several hours. The reaction was monitored by TLC. After the reaction was completed, water was added to the system to quench the reaction, and the pH of the aqueous phase system was adjusted to neutral with saturated sodium bicarbonate. The organic phase was extracted with dichloromethane, and then dried with anhydrous magnesium sulfate, filtered, decompressed and dried, and purified by column chromatography to obtain the product 4-(3-((4-chloro-7-methoxyquinazolin-6-yl)oxy)propyl)morpholine; the reaction temperature was 60-100°C, and the reaction time was 6h-18h.

[0015] (7): A certain amount of 7-methoxy-6-(3-morpholinopropoxy)quinazolin-4(3H)-one was dissolved in a phosphorus oxychloride solution, and the system was heated to react for several hours. The reaction was monitored by TLC. After the reaction was completed, water was added to the system to quench the reaction, and the pH of the aqueous phase system was adjusted to neutral with saturated sodium bicarbonate. The organic phase was extracted with dichloromethane, and then dried with anhydrous magnesium sulfate. The organic phase was filtered and dried under reduced pressure. The product 4-(3-((4-chloro-7-methoxyquinazolin-6-yl)oxy)propyl)morpholine was purified by column chromatography. The microwave reaction gear was set to 6-8 gears, the temperature was set to 60-120°C, and the time was set to 30-60min.

[0016] (8): A certain amount of 4-(3-((4-chloro-7-methoxyquinazolin-6-yl)oxy)propyl)morpholine and m-alkynylaniline are dissolved in an isopropanol solution, and the system is heated to react for several hours. The reaction is monitored by TLC. After the reaction is completed, the product N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropyloxy)quinazolin-4-amine is obtained by suction filtration; the reaction temperature is 60-100°C, the reaction time is 6h-18h, and the molar ratio of the 4-(3-((4-chloro-7-methoxyquinazolin-6-yl)oxy)propyl)morpholine to m-alkynylaniline is 1:3-6.

[0017] (9): A certain amount of 4-(3-((4-chloro-7-methoxyquinazolin-6-yl)oxy)propyl)morpholine and m-alkynylaniline are dissolved in an isopropanol solution, the system is heated to react for several hours, and the reaction is monitored by TLC. After the reaction is completed, the product N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropyloxy)quinazolin-4-amine is obtained by suction filtration; the microwave reaction power is set to 300-400 watts, the temperature is set to 55-75°C, and the time is set to 30-60 minutes. The molar ratio of the 4-(3-((4-chloro-7-methoxyquinazolin-6-yl)oxy)propyl)morpholine to m-alkynylaniline is 1:3-6.

[0018] (10): A certain amount of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine and 2-bromo-5-fluorobenzyl azide are dissolved in a mixed solution of tert-butyl alcohol / water / tetrahydrofuran, and the system is heated to react for several hours. The reaction is monitored by TLC. After the reaction is completed, the gefitinib triazole product is purified by column chromatography; the reaction temperature is 60-100°C, the reaction time is 6h-18h, and the molar ratio of the N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine to benzyl azide is 1:1.1-1.6.

[0019] The invention discloses an application of gefitinib-linked triazole derivatives in the preparation of drugs for treating or preventing lung cancer.

[0020] Technical advantages of the present invention:

[0021] 1. The present invention obtains a series of novel gefitinib-linked triazole derivatives.

[0022] 2. This type of compound has a good inhibitory effect on wild-type lung cancer tumor cells, can target MMP9 as an MMP9 inhibitor, and thus inhibit the migration and metastasis of wild-type lung cancer tumors; and can also induce DNA damage in hepG2 cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 The H NMR spectrum of compound 7a obtained in Example 13

[0024] Figure 2 The H NMR spectrum of compound 7j obtained in Example 15

[0025] Figure 3 The H NMR spectrum of compound 7q obtained in Example 15 DETAILED DESCRIPTION

[0026] The above contents of the present invention are further described in detail below through examples, but this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples, and all technologies implemented based on the above contents of the present invention belong to the scope of the present invention.

[0027] Example 1

[0028]

[0029] Dissolve methyl 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate (15 g) in acetic acid (100 mL) solution, cool the system to below 10°C, add a mixture of nitric acid (5.6 g) and sulfuric acid (5.7 g) dropwise, and gradually warm the system to room temperature after the addition. The system reacts at room temperature for 24 hours, and the reaction is monitored by TLC. After the reaction is completed, water is added to the system to quench the reaction, and the mixture is extracted with ethyl acetate, dried over anhydrous sodium sulfate, evaporated to dryness, and the crude product is purified by column chromatography to obtain 10 g of methyl 2-nitro 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate.

[0030] Example 2

[0031] Dissolve methyl 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate (15 g) in methanesulfonic acid (100 mL) solution, cool the system to below 10°C, add a mixture of nitric acid (5.6 g) and methanesulfonic acid (5.6 g) dropwise, and gradually warm the system to room temperature after the addition. The system reacts at room temperature for 8 hours, and the reaction is monitored by TLC. After the reaction is completed, water is added to the system to quench the reaction, and the mixture is extracted with ethyl acetate, dried over anhydrous sodium sulfate, evaporated to dryness, and the crude product is purified by column chromatography to obtain 13 g of methyl 2-nitro 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate.

[0032] Example 3

[0033] Methyl 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate (15 g) was dissolved in nitromethane (100 mL) solution, the system was cooled to 0-10° C., the system was saturated with boron trifluoride gas (until the reaction system could no longer dissolve boron trifluoride, and the pressure of the reaction system began to change significantly through the pressure valve), methyl nitrate (6.7 g) was added, and after the addition, the system gradually warmed to room temperature. The system was reacted at room temperature for 7.5 hours. The reaction was completed by TLC monitoring, 200 mL of water was added to the system to quench the reaction, and the reaction system was extracted with 100 mL of ethyl acetate 5 times. The organic phases were combined and dried over anhydrous sodium sulfate, and evaporated to dryness to obtain 14.7 g of methyl 2-nitro-4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate.

[0034] Example 4

[0035] In a reaction flask, methyl 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate (1.5 g) was dissolved in acetic acid (10 mL) solution to prepare solution A; a mixed solution of nitric acid (0.6 g) and sulfuric acid (1.1 g) was dissolved to prepare solution B (volume was about 1 mL); A and B were simultaneously introduced into a microchannel reactor at flow rates of 1 mL / min and 0.1 mL / min, respectively, and the reactor temperature was set to 0°C. After the reaction was completed, the reaction solution discharged from the reactor was collected and poured into ice water, a large amount of solid product appeared, and the product was obtained after recrystallization with isopropanol, obtaining 1.41 g of methyl 2-nitro 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate. 1 H NMR (400MHz, CDCl3): δ7.45(s,1H),7.10(s,1H),4.18(t,2H),3.94(s,3H),3.93(s,3H),3.73(t,4H),2.55-2.47(m,6H),2.06(t,2H).

[0036] Example 5

[0037]

[0038] The nitration product of the previous step, methyl 2-nitro-4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate (1 g), was weighed and dissolved in anhydrous methanol (10 mL). Pd / C (10%, 0.1 g) was added for hydrogenation reaction. The system was reacted overnight at room temperature and the reaction was tracked by TLC. When the raw material disappeared, palladium carbon was directly filtered out of the system. The system was evaporated to remove excess solvent and purified by column chromatography to obtain 0.7 g of solid product methyl 2-amino-4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate.

[0039] Example 6

[0040] The nitration product of the previous step, 2-nitro-4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester (1.2 g), was weighed and dissolved in acetone (20 mL). A solution of titanium trichloride (30%) and hydrochloric acid (50 mL) was added dropwise to the reaction system under an ice bath. After the addition was completed, the system was gradually warmed to room temperature and reacted overnight. The reaction was tracked by TLC until the starting material disappeared. The system was poured into ice water (200 mL) and extracted with ethyl acetate (70 mL×3). The system was evaporated to remove excess solvent and purified by column chromatography to obtain 0.76 g of a solid product, 2-amino-4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester.

[0041] Example 7

[0042] In the flow hydrogenation reaction device (self-assembly), the hydrogenation flow system consists of a gas flow meter, a micro mixer, a micro packed bed and a back pressure valve with a pressure resistance of 15 bar. A mixture containing the above-mentioned methyl 2-nitro-4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate (1 g) and methanol (20 mL) is transported by a pressure pump (flow rate 0.5 mL / min); the hydrogen in the high-pressure cylinder enters the micro reaction system through the gas flow meter, and the flow rate is 1 mL / min. The liquid phase and the gas phase were combined through a T-tube and entered a micromixer, and the reaction temperature of the system was controlled at 25°C; the reaction flow passed through a micropacked bed (0.1 g 10% Pd / C, 20.0 g SiO2: 5 mL internal volume) with a residence time of 10.0 min; the reaction flow was then collected in a 50 mL conical flask and concentrated in vacuo, and the crude product was purified by column chromatography (DCM / MeOH=100:1) to obtain 0.87 g of methyl 2-amino 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate; 1 H NMR (400MHz, DMSO-d6): δ7.54(s,1H),7.14(s,1H),6.43(s,2H),4.28(t,2H), 3.97(s,3H),3.91(s,3H),3.63(t,4H),2.57-2.52(m,6H),2.16-2.15(m,2H).

[0043] Example 8

[0044]

[0045] The methyl 2-amino-4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate (4.0 g) obtained in the previous step and ammonium formate (2.0 g) were dissolved in DMF (30 mL). The system was heated to 165° C. under a nitrogen environment and reacted for 4 hours. The reaction was tracked by TLC. After the reaction was completely completed, the system was poured into ice water, extracted with ethyl acetate, and the organic phase was separated and dried over anhydrous magnesium sulfate. The phase was filtered and dried under reduced pressure. Finally, it was purified by column chromatography to obtain 2.7 g of 7-methoxy-6-(3-morpholinopropoxy)quinazoline-4(3H)-one.

[0046] Example 9

[0047] In a microwave chemical reactor (MCR-3), dissolve the 2-amino 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester (4.0 g) and ammonium formate (2.0 g) obtained in the previous step into DMA (30 mL). Turn on the power, insert the temperature sensor, set the microwave reaction power to: 300-400 watts, set the temperature to 80°C, and set the time to: 15 min. After the reaction is completely completed. Pour the system into ice water, slowly stir the system, wait for the product to precipitate, and filter to obtain the product 7-methoxy-6-(3-morpholinopropoxy)quinazoline-4(3H)-one 2.95 g; 1 H NMR (400MHz, DMSO-d6) δ7.97 (s, 1H), 7.44 (s, 1H), 7.12 (s, 1H), 4.11 (t, J = 6.5Hz, 2H), 3. 90(s,3H),3.58(t,J=4.6Hz,4H),2.44(t,J=7.0Hz,2H),2.37(s,4H),1.99-1.80(m,2H).

[0048] Example 10

[0049] In a microwave chemical reactor (MCR-3), dissolve the 2-amino 4-methoxy-3-(3-(morpholine-4-yl) propoxy) methyl benzoate (4.0 g) and ammonium formate (2.0 g) obtained in the previous step in DMSO (20 mL). Turn on the power, insert the temperature sensor, set the microwave reaction power to: 300-400 watts, set the temperature to 80°C, and set the time to: 15 min. After the reaction is completely completed. Pour the system into ice water, slowly stir the system, wait for the product to precipitate, and filter to obtain 3.01 g of the product 7-methoxy-6-(3-morpholine propoxy) quinazoline-4(3H)-one.

[0050] Embodiment 11

[0051]

[0052] The compound 7-methoxy-6-(3-morpholinopropoxy)quinazolin-4(3H)-one (2.6 g) was dissolved in phosphorus oxychloride (10.0 mL), and the system was heated to reflux. After the reaction lasted for 18 hours, TLC was continued to track the reaction. After the reaction was completely completed, the system was poured into ice water, and the pH of the aqueous phase system was adjusted to neutral with saturated sodium bicarbonate. The organic phase was extracted with dichloromethane, and then dried over anhydrous magnesium sulfate, filtered, and dried under reduced pressure. The product 4-(3-((4-chloro-7-methoxyquinazolin-6-yl)oxy)propyl)morpholine 2.1 g was obtained by column chromatography.

[0053] Example 12

[0054] In a microwave chemical reactor, 7-methoxy-6-(3-morpholine propoxy) quinazoline-4(3H)-one (2.6g) was dissolved in phosphorus oxychloride (10.0mL); the power was turned on, the temperature sensor was inserted, the microwave reaction gear was set to 90°C, and the time was set to 45min. After the reaction was completely completed. The system was poured into ice water, the pH of the aqueous phase system was adjusted to neutral with saturated sodium bicarbonate, extracted with dichloromethane, the organic phase was separated, and then dried with anhydrous magnesium sulfate, filtered and decompressed to obtain 2.3g of the product 4-(3-((4-chloro-7-methoxyquinazoline-6-yl)oxy)propyl)morpholine. 1 H NMR(400MHz,DMSO-d6)δ8.86(s,1H),7.43(s,1H),7.38(s,1H),4.23(t,2H ),3.95(s,3H),3.57(t,4H),2.43(t,2H),2.37(s,4H),2.03-1.92(m,2H).

[0055] Embodiment 13

[0056]

[0057] 4-(3-((4-chloro-7-methoxyquinazolin-6-yl)oxy)propyl)morpholine (1.5 g) was dissolved in 40 mL of isopropanol, and m-alkynylaniline (1.58 g) was added. The system was heated to reflux and reacted for 10 hours. The reaction was tracked by TLC. When the reaction was completely completed and a large amount of solid product was precipitated in the system, 1.2 g of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropyloxy)quinazoline-4-amine was obtained by suction filtration.

[0058] Embodiment 14

[0059] In a microwave chemical reactor, 4-(3-((4-chloro-7-methoxyquinazolin-6-yl)oxy)propyl)morpholine (1.5g) was dissolved in 40mL of isopropanol, and m-alkynylaniline (1.58g) was added. Turn on the power, insert the temperature sensor, set the microwave reaction power to 350-450 watts, set the temperature to 75°C, and set the time to 30min. After the reaction is completely completed. Pour the system into ice water, slowly stir the system, wait for the product to precipitate, and filter to obtain 1.4g of off-white solid product N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinepropoxy)quinazoline-4-amine.

[0060] Embodiment 15

[0061]

[0062] Synthesis of the target product N-(3-(1-(2-bromo-5-fluorobenzyl)-1H-1,2,3-triazol-4-yl)phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (7a): In a reaction flask, N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (250 mg), 2-bromo-5-fluorobenzyl azide (160 mg), 10 mL of tert-butyl alcohol / 10 mL of water were added in sequence. mL / tetrahydrofuran 10mL, copper sulfate pentahydrate (15mg) and sodium ascorbate (12mg), react at 90℃ for 12h. After the raw material is completely reacted and converted into the product, 30mL of dichloromethane is added, and the reaction liquid is filtered to obtain a yellow liquid. The organic phase is separated, and the aqueous phase is extracted twice with 15mL of dichloromethane. The organic phases are combined, dried over anhydrous magnesium sulfate, and the solvent is evaporated to obtain a yellow solid. 162mg of light yellow product 7a is obtained by column chromatography.

[0063] Example 16

[0064]

[0065] In a parallel reactor, N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (250 mg), 2-bromo-5-fluorobenzyl azide (160 mg), tert-butanol 10 mL / water 10 mL / tetrahydrofuran 10 mL, copper sulfate pentahydrate (15 mg) and sodium ascorbate (23 mg) were added in sequence, and the reaction was carried out at 90°C for 12 h. After the raw materials were completely reacted and converted into products, the system was evaporated to remove excess tetrahydrofuran and tert-butanol, 50 mL of secondary water was added, and the mixture was placed in an ultrasonic instrument for 20 min. The mixture was allowed to stand for 1 h until solid was formed. After centrifugation for 10 min, the supernatant was removed, and a small amount of methanol was used for recrystallization. The product 368 mg of light yellow product 7a was obtained by suction filtration (due to the high polarity of the product, it is not easy to purify. After improving the purification method, the yield is improved). 1 H NMR (400MHz, DMSO-d6) δ9.63(s,1H),8.64(s,1H),8.26(s,1H),8.13-8.06(m,1H),7.90(d,J=8.0Hz,1H),7.77-7.75(m,1H),7.58(d,J=7.6Hz ,1H),7.45(s,1H),7.30-7.15(m,2H),5.75(s,2H),4.25-4.15(m,2H), 3.98(s,3H),3.61-3.53(m,4H),2.44-2.37(m,3H),2.09-1.92(m,2H).

[0066] Embodiment 17

[0067]

[0068] In a parallel reactor, N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (250 mg), 2-fluoro-4-bromobenzyl azide (160 mg), 10 mL of tert-butyl alcohol / 10 mL of water / 10 mL of tetrahydrofuran, copper sulfate pentahydrate (15 mg) and sodium ascorbate (23 mg) were added in sequence and reacted at 90° C. for 12 h. After the raw materials were completely reacted and converted into products, the system was evaporated to remove excess tetrahydrofuran and tert-butyl alcohol, and then added 50mL secondary water, placed in an ultrasonic instrument for 20 minutes, let stand for 1 hour, wait for solid to form, centrifuge for 10 minutes, remove the supernatant, recrystallize with a small amount of methanol, and filter to obtain 352 mg of the product N-(3-(1-(4-bromo-2-fluorobenzyl)-1H-1,2,3-triazol-4-yl)phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine, with a yield of 91% (due to the high polarity of the product, it is not easy to purify. After improving the purification method, the yield is improved). 1 H NMR(400MHz,Chloroform-d)δ9.60(s,1H),8.64(s,1H),8.26(s,1H),8.02(s,1H),7.91(d,J=8.0Hz,1H),7.65(d,J=9.6Hz,1H),7.56(d,J=7 .6Hz,1H),7.54-7.31(m,3H),5.71(s,2H),4.21(t,J=6.3Hz,2H),3.97(s,3H),3.64-3.52(m,4H),2.43-2.40(m,3H),2.01(t,J=6.8Hz,2H).

[0069] The preparation methods of target compounds 7c-7z are similar to those of 7a and 7b, except that the active group substituents with azide structures are different. The structural characterization data are as follows:

[0070]

[0071] Target compound N-(3-(1-(3-chloro-4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (7c): yield: 89%.

[0072] The target compound N-(3-(1-(2-chloro-6-fluorobenzyl)-1H-1,2,3-triazol-4-yl)phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (7d): the yield is: 95%.

[0073] The target compound 7-methoxy-6-(3-morpholinopropoxy)-N-(3-(1-(2-nitrobenzyl)-1H-1,2,3-triazol-4-yl)phenyl)quinazolin-4-amine (7e): the yield is: 91%.

[0074] The target compound 7-methoxy-6-(3-morpholinopropoxy)-N-(3-(1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl)phenyl)quinazolin-4-amine (7f): the yield is: 75%.

[0075] Target compound N-(3-(1-(2-fluorobenzyl)-1H-1,2,3-triazol-4-yl)phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (7 g): yield: 80%.

[0076] The target compound 7-methoxy-6-(3-morpholinopropoxy)-N-(3-(1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)phenyl)quinazolin-4-amine (7h): the yield is: 60%.

[0077] Target compound N-(3-(1-(4-iodobenzyl)-1H-1,2,3-triazol-4-yl)phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (7i): yield: 85%.

[0078] The target compound N-(3-(1-(3-chlorobenzyl)-1H-1,2,3-triazol-4-yl)phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (7j): the yield is: 87%.

[0079] Target compound N-(3-(1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (7k): yield: 90%.

[0080] The target compound 7-methoxy-N-(3-(1-(2-methylbenzyl)-1H-1,2,3-triazol-4-yl)phenyl)-6-(3-morpholinopropoxy)quinazolin-4-amine (71): the yield is: 85%.

[0081] Target compound N-(3-(1-(3,5-dimethylbenzyl)-1H-1,2,3-triazol-4-yl)phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (7m): yield: 84%.

[0082] Target compound 4-fluoro-2-((4-(3-((7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl)amino)phenyl)-1H-1,2,3-triazol-1-yl)methyl)benzonitrile (7n): yield: 58%.

[0083] The target compound N-(3-(1-(3,5-dimethoxybenzyl)-1H-1,2,3-triazol-4-yl)phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (7o): the yield is: 75%.

[0084] Target compound N-(3-(1-(3-iodobenzyl)-1H-1,2,3-triazol-4-yl)phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (7p): yield: 92%.

[0085] The target compound N-(3-(1-(2-bromobenzyl)-1H-1,2,3-triazol-4-yl)phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (7q) had a yield of 84%.

[0086] The target compound N-(3-(1-(4-bromobenzyl)-1H-1,2,3-triazol-4-yl)phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (7r): the yield is: 91%.

[0087] The target compound 2-((4-(3-((7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl)amino)phenyl)-1H-1,2,3-triazol-1-yl)methyl)benzonitrile (7s): yield: 87%.

[0088] Target compound N-(3-(1-(3,5-dibromobenzyl)-1H-1,2,3-triazol-4-yl)phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (7t): yield: 95%.

[0089] Target compound 7-methoxy-N-(3-(1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)phenyl)-6-(3-morpholinopropoxy)quinazolin-4-amine (7u): yield: 82%.

[0090] Target compound 7-methoxy-N-(3-(1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)phenyl)-6-(3-morpholinopropoxy)quinazolin-4-amine (7v): yield: 87%.

[0091] The target compound 7-methoxy-N-(3-(1-(3-methoxyphenyl)-1H-1,2,3-triazol-4-yl)phenyl)-6-(3-morpholinopropoxy)quinazolin-4-amine (7w): the yield is: 89%.

[0092] Target compound 7-methoxy-N-(3-(1-(3-nitrophenyl)-1H-1,2,3-triazol-4-yl)phenyl)-6-(3-morpholinopropoxy)quinazolin-4-amine (7x): yield: 85%.

[0093] The target compound 7-methoxy-N-(3-(1-(3-nitrophenyl)-1H-1,2,3-triazol-4-yl)phenyl)-6-(3-morpholinopropoxy)quinazolin-4-amine (7y): the yield is: 85%.

[0094] The target compound 7-methoxy-N-(3-(1-(lenalidomide)-1H-1,2,3-triazol-4-yl)phenyl)-6-(3-morpholinopropoxy)quinazolin-4-amine (7z): the yield is: 93%.

[0095] Example 16

[0096] The obtained compound and gefitinib were dissolved in DMSO and prepared into a mother solution with a final concentration of 12800 μM. The compound was diluted to different concentrations with the culture medium corresponding to the cells for subsequent experiments (0, 2, 4, 8, 16, 32 μmol / L (the final concentration of DMSO did not exceed 0.1% in the experiment). Lung cancer cells in the logarithmic growth phase were inoculated in a 96-well plate at a density of 5×103 cells per well and cultured in a cell culture incubator at 37°C and 5% CO2. After the cells adhered to the wall, the cells were divided into a normal control group, a blank group, and different concentrations of drugs (0, 2, 4, 8, 16, 32 μmol / L). Except for the normal control group cells, the corresponding drugs were added to the other groups and cultured at 37°C and 5% CO2 for 48 hours, with 3 replicates for each group. According to the CCK8 kit instruction manual (No. C0039, Beyotime), lung cancer cells in the logarithmic growth phase were inoculated at a density of 5×103 cells per well. 3The cells were inoculated in a 96-well plate at a density of 100 μl and cultured in a cell culture incubator at 37°C and 5% CO2. After the cells adhered to the wall, they were divided into a normal control group, a blank group, and different drug concentration groups (0, 2, 4, 8, 16, and 32 μmol / L). Except for the normal control group cells, the corresponding drugs were added to the other groups and cultured for 48 hours at 37°C and 5% CO2. Each group had 3 replicate wells. 10 μl of CCK8 reagent was added to each well, and the cells were placed in a 37°C cell culture incubator away from light for 1-4 hours. The absorbance (optical density, OD) value was detected at a wavelength of 450 nm using an enzyme reader (Bio-Tek). The inhibition rate of cell growth in each group was calculated, inhibition rate (%) = [(OD value of the experimental group - OD value of the blank group) / (OD value of the control group - OD value of the blank group)] × 100%, and the half inhibitory concentration (half inhibitory concentration, IC) of the drug was further calculated. 50 ). The experiment was repeated 3 times. 10 μl of CCK8 reagent was added to each well, and the cells were placed in a 37°C cell culture incubator in the dark for 1-4 hours. The absorbance (optical density, OD) value was detected at a wavelength of 450 nm using a microplate reader (Bio-Tek). The inhibition rate of cell growth in each group was calculated, inhibition rate (%) = [(OD value of experimental group - OD value of blank group) / (OD value of control group - OD value of blank group)] × 100%, and the half inhibitory concentration (half inhibitory concentration, IC50) of the drug was further calculated. The experiment was repeated 3 times.

[0097]

[0098] Embodiment 17

[0099] After treatment with compound 7a, the total apoptosis rates of H1299 cells were 18.3% (2 μM), 28.3% (4 μM) and 47.9% (8 μM), respectively ( Figure 3). After treatment with compound 7j, the total apoptosis rates of H1299 cells were 13.2% (2μM), 24.5% (4μM) and 63.3% (8μM), respectively. After treatment with compound 7q, the total apoptosis rates of H1299 cells were 20.43% (2μM), 43.2% (4μM) and 77.4% (8μM), respectively. Compared with the control group, the apoptosis rate gradually increased with the increase of drug concentration (P<0.01, P<0.05). The above results indicate that 7a, 7j and 7q can significantly promote the apoptosis of H1299 lung cancer cell lines, and are concentration-dependent. After treatment with compound 7a, the migration closure rates of H1299 cells were 73.8% (2μM), 53.6% (4μM) and 26.1% (8μM), respectively. After treatment with compound 7j, the migration shut-off rates of H1299 cells were 76.5% (2μM), 65.5% (4μM) and 47.8% (8μM), respectively. After treatment with compound 7q, the migration shut-off rates of H1299 cells were 72.59% (2μM), 62.42% (4μM) and 49.79% (8μM), respectively. Compounds 7a, 7j and 7q were able to inhibit the cloning of H1299 cells at 1μM. Compounds 7a, 7j and 7q were able to reduce the MMP9 protein in H1299 cells to about 50% at 8μM, respectively, so this class of compounds can be used as MMP9 inhibitors.

[0100] Embodiment 18

[0101] We prepared compounds 7a-7z at a concentration of 10 μM and tested their inhibitory activity against hepG2 liver cancer cells. We found that most compounds showed activity superior to that of gefitinib itself. The IC50 values ​​of compounds 7i and 7p were 3.08 and 3.60 μM, respectively, and the survival rates of these two compounds against L02 cells at 16 μM were 76.86% and 47.58%, respectively, showing safety. Compounds 7i and 7p at a concentration of 2 μM can reduce the migration and invasion ability of hepG2 cells for 24 hours, and can cause DNA damage in hepG2 cells at a concentration of 2 μM, and can cause an increase in H2AX protein expression by about 42% compared with the blank control.

[0102]

[0103] The above embodiments describe the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for illustrating the principles of the present invention. Without departing from the scope of the principles of the present invention, the present invention may have various changes and improvements, and these changes and improvements all fall within the scope of protection of the present invention.

Claims

1. A gefitinib-linked triazole derivative and its preparation method and application, Features The structure of the gefitinib-linked triazole derivative is: Wherein R is benzyl, phenyl or other heterocyclic structures.

2. A method for preparing a gefitinib-linked triazole derivative according to claim 1, Features The specific process is as follows: a certain amount of 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester is dissolved in acetic acid solution, the system is cooled to below 10°C, a certain amount of nitric acid and sulfuric acid mixed solution is added dropwise, the system is gradually heated to room temperature after the addition is completed, the system reacts at a certain temperature for several hours, TLC monitors the reaction, after the reaction is completed, water is added to the system to quench the reaction, ethyl acetate is extracted, the water is dried over anhydrous sodium sulfate, and the crude product is evaporated to dryness and purified by column chromatography to obtain 2-nitro 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester; the molar ratio of the feed amount of 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester to nitric acid and sulfuric acid is 1:1~1.3:1~1.3; the reaction temperature is 20~50 ℃; or a certain amount of 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester is dissolved in a methanesulfonic acid solution, the system is cooled to below 10℃, a certain amount of a mixed solution of nitric acid and methanesulfonic acid is added dropwise, the system gradually warms to room temperature after the addition is completed, the system reacts at a certain temperature for several hours, and the reaction is monitored by TLC. After the reaction is completed, water is added to the system to quench the reaction, ethyl acetate is extracted, the water is dried over anhydrous sodium sulfate, and the crude product is evaporated to dryness and purified by column chromatography to obtain 2-nitro 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester; the molar ratio of the feed amount of 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester to nitric acid to methanesulfonic acid is 1:1~1.3:1~1.3; the reaction temperature is 20~50℃.

3. A method for preparing a gefitinib-linked triazole derivative according to claim 1, Features The specific process is as follows: a certain amount of methyl 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate is dissolved in a nitromethane solution, the system is cooled to below 10°C, the system is saturated with boron trifluoride gas, a certain amount of methyl nitrate is added, the system is gradually heated to room temperature after the addition, the system reacts at room temperature until the reaction is monitored by TLC, after the reaction is completed, water is added to the system to quench the reaction, ethyl acetate is extracted, the water is dried over anhydrous sodium sulfate, the crude product is evaporated to dryness, and then purified by column chromatography to obtain methyl 2-nitro 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate; the molar ratio of the feeding amount of methyl 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoate to methyl nitrate is 1:1-3.

4. A method for preparing a gefitinib-linked triazole derivative according to claim 1, Features The specific process is as follows: a certain amount of 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester is dissolved in acetic acid solution to prepare solution A; a certain amount of nitric acid and sulfuric acid mixed solution is dissolved to prepare solution B; A and B are respectively introduced into a microchannel reactor at a certain flow rate, and the reactor temperature is set to 0°C. After the reaction is completed, the reaction liquid discharged from the reactor is collected and poured into ice water, and a large amount of solid products appear. The product is obtained by recrystallization with isopropanol to obtain 2-nitro 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester; the molar ratio of the feed amount of 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester to nitric acid and sulfuric acid is 1:1~2:1~3.

5. A method for preparing a gefitinib-linked triazole derivative according to claim 1, Features The specific process is as follows: a certain amount of 2-nitro 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester is dissolved in anhydrous methanol solution, a certain amount of palladium carbon is added in batches at room temperature, the system reacts at the corresponding temperature for several hours after the addition is completed, and the reaction is monitored by TLC. After the reaction is completed, the system filters out excess palladium carbon, evaporates to dryness, and the crude product is purified by column chromatography to obtain 2-amino 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester; the molar ratio of the feed amount of 2-nitro 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester to palladium carbon is 1:0.02-0.2; the reaction temperature is 20-60°C.

6. A method for preparing a gefitinib-linked triazole derivative according to claim 1, Features The specific process is as follows: a certain amount of 2-amino 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester and ammonium formate are dissolved in a DMF solution, the system is heated to react for several hours, and the reaction is monitored by TLC. After the reaction is completed, water is added to the system to quench the reaction, ethyl acetate is extracted, and the water is dried over anhydrous sodium sulfate. After evaporation, the crude product is purified by column chromatography to obtain 7-methoxy-6-(3-morpholinopropoxy)quinazolin-4(3H)-one; the molar ratio of the 2-amino 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester to the ammonium formate is 1:3-1.6; the reaction temperature is 120-170°C; or a certain amount of 2-amino 4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester and ammonium formate are dissolved in DMA or DMSO solution, the system is heated to react for several hours, and the reaction is monitored by TLC. After the reaction is completed, water is added to the system to quench the reaction, ethyl acetate is extracted, and the water is dried over anhydrous sodium sulfate. After evaporation, the crude product is purified by column chromatography to obtain 7-methoxy-6-(3-morpholinopropoxy)quinazolin-4(3H)-one; the molar ratio of the 2-amino-4-methoxy-3-(3-(morpholin-4-yl)propoxy)benzoic acid methyl ester to the ammonium formate is 1:3-1.6; the reaction temperature is 60-100°C, and the microwave reaction time is set to: 15min-30min.

7. The method for preparing a gefitinib-linked triazole derivative according to claim 1, Features The specific process is: a certain amount of 7-methoxy-6-(3-morpholinopropoxy)quinazolin-4(3H)-one is dissolved in a phosphorus oxychloride solution, the system is heated to react for several hours, and the reaction is monitored by TLC. After the reaction is completed, water is added to the system to quench the reaction, and the pH of the aqueous phase system is adjusted to neutral with saturated sodium bicarbonate, extracted with dichloromethane, and the organic phase is separated, and then dried with anhydrous magnesium sulfate, filtered, decompressed and spin-dried, and purified by column chromatography to obtain the product 4-(3-((4-chloro-7-methoxyquinazolin-6-yl)oxy)propyl)morpholine; the reaction temperature is 60-100°C, and the reaction time is 6h-18h; or A certain amount of 7-methoxy-6-(3-morpholinopropoxy)quinazolin-4(3H)-one is dissolved in a phosphorus oxychloride solution, and the system is heated to react for several hours. The reaction is monitored by TLC. After the reaction is completed, water is added to the system to quench the reaction, and the pH of the aqueous phase system is adjusted to neutral with saturated sodium bicarbonate. The organic phase is extracted with dichloromethane, and then dried with anhydrous magnesium sulfate, filtered, decompressed and spin-dried, and purified by column chromatography to obtain the product 4-(3-((4-chloro-7-methoxyquinazolin-6-yl)oxy)propyl)morpholine; the microwave reaction temperature is set to 60-120°C, and the time is set to: 30-60min.

8. The method for preparing a gefitinib-linked triazole derivative according to claim 1, Features The specific process is: a certain amount of 4-(3-((4-chloro-7-methoxyquinazolin-6-yl)oxy)propyl)morpholine and meta-alkynylaniline are dissolved in an isopropanol solution, the system is heated to react for several hours, TLC is used to monitor the reaction, and after the reaction is completed, the product N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropyloxy)quinazolin-4-amine is obtained by suction filtration; the reaction temperature is 60-100°C, the reaction time is 6h-18h, and the molar ratio of the 4-(3-((4-chloro-7-methoxyquinazolin-6-yl)oxy)propyl)morpholine to meta-alkynylaniline is 1:3-6.

9. The method for preparing a gefitinib-linked triazole derivative according to claim 1, Features The specific process is: a certain amount of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine and 2-bromo-5-fluorobenzyl azide are dissolved in a mixed solution of tert-butyl alcohol / water / tetrahydrofuran, the system is heated to react for several hours, TLC is used to monitor the reaction, and after the reaction is completed, column chromatography is used for purification to obtain the gefitinib triazole product; the reaction temperature is 60-100°C, the reaction time is 6h-18h, and the molar ratio of the N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine to the benzyl azide is 1:1.1-1.

6.

10. The gefitinib-linked triazole derivative as claimed in claim 1 can target MMP9 protein as an MMP9 inhibitor, thereby inhibiting the migration and metastasis of wild-type lung cancer cells and liver cancer cells.

Citation Information

Patent Citations

  • Quinazoline derivatives as well as preparation method and application thereof

    CN109096208A